I’m excited that today’s episode covers the new postpartum depression medication, Zuranalone (brand name Zurzuvae). This is the first pill for PPD and was just recently approved by the FDA. It differs from the IV infusion Braxanalone, which was FDA approved in 2019. As with any new medication, there are many questions to consider if we are to stay ahead of any misinformation and hesitations. Join us to learn what you need to know and understand about this fantastic new tool in the treatment of PPD. 

Dr. Samantha Meltzer-Brody is the Assad Meymandi Distinguished Professor and Chair of the Department of Psychiatry at the University of North Carolina at Chapel Hill. She is an internationally recognized reproductive psychiatrist and clinician-scientist who also directs the UNC Center for Women’s Mood Disorders. Her work has focused on developing a comprehensive integrated clinical and research project in women’s mood disorders across the reproductive life cycle. Dr. Meltzer-Brody investigates the epidemiologic and biological predictors of perinatal biomarkers, as well as the impact of adverse life events. 

Show Highlights:

Resources:

Connect with Dr. Samantha Meltzer-Brody:  

Visit www.postpartum.net for resources and support! 

Visit www.postpartum.net/professionals/certificate-trainings/ for information on the grief course.  

Visit my website, www.wellmindperinatal.com, for more information, resources, and courses you can take today!

Learn more about your ad choices. Visit podcastchoices.com/adchoices